Flash Finance

Zydus Lifesciences LimitedZYDUSLIFECorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹1,123.00
MCap ₹112,020 Cr · P/E 31.5
Zydus Lifesciences Limited — Stock analysis & AI research Zydus Lifesciences Limited — Multibagger AI analysis Zydus Lifesciences Limited — Seasonality — best & worst months Zydus Lifesciences Limited — Technical indicators & charts Zydus Lifesciences Limited — Technical setup — score, trend, support & resistance Zydus Lifesciences Limited — Ascending Triangle pattern forming Zydus Lifesciences Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 GARP Stocks (PEG Below 1) ⚖️ vs Sun Pharmaceutical⚖️ vs Laurus Labs 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹3,741 Cr
Sales · Mar 2026
-35.7% YoY
₹1,989 Cr
Operating Profit · Mar 2026
-47.3% YoY
53.2%
OPM % · Mar 2026
-17.9% YoY
₹1,722 Cr
Net Profit · Mar 2026
-38.8% YoY
₹17.11
EPS · Mar 2026
-38.8% YoY

📝 Zydus Lifesciences Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Zydus Lifesciences Limited reported revenue of ₹3,741 crore for the quarter ended March 2026 (Q4 FY26), down 35.7% from ₹5,820 crore in the same quarter last year, and up 63.8% sequentially over the December 2025 quarter.

Net profit fell 38.8% year-on-year to ₹1,722 crore, from ₹2,814 crore. Earnings per share (EPS) came in at ₹17.11.

Operating profit stood at ₹1,989 crore — an operating margin (OPM) of 53.2%, compared with 64.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Zydus Lifesciences Limited posted revenue of ₹11,484 crore, a decline of 24.0% over FY25, with a net profit of ₹3,560 crore (down 38.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹11,484 crore with a net profit of ₹3,560 crore.

Valuation snapshot

At the current price of ₹1,123.00, ZYDUSLIFE has a market capitalisation of ₹112,020 crore and a trailing P/E of about 31.5.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 4th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 75.01%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 11.28%, public shareholders 6.66% of Zydus Lifesciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹112,020 Cr
Current Price ?
₹1,123.0
P/E ?
31.47below ind
Industry P/E ?
35.00
P/B ?
4.73
P/S ?
9.75
P/FCF ?
82.92
Enterprise Value ?
₹119,462 Cr
EV/EBITDA ?
30.43
PEG ?
0.98
Earnings Yield ?
2.8%
Dividend Yield ?
0.09%
Profitability & Returns
Sales (TTM) ?
₹11,484 Cr
OPM ?
34.2%
Profit after tax (TTM) ?
₹3,560 Cr
EPS (TTM) ?
₹35.69
ROCE ?
17.0%
ROE ?
15.0%
ROA ?
10.5%
Growth
Sales — latest qtr ?
₹3,741 Cr
PAT — latest qtr ?
₹1,722 Cr
YoY qtr sales growth ?
-35.7%
YoY qtr profit growth ?
-38.8%
Sales growth (3y) ?
10%
Sales growth (5y) ?
8%
Profit growth (3y) ?
32%
Profit growth (5y) ?
18%
Financial Health
Debt ?
₹7,442 Cr
Debt to Equity ?
0.31
Interest Coverage ?
7.0
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.01%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-1.8%
Return 6 months ?
19.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 2,0872,5792,9562,1592,3713,3324,1602,6212,5165,8202,5882,8712,2843,741 -35.7% +63.8%
Operating Profit 4597721,1416496991,5692,3739426483,7735851,1521991,989 -47.3% +899.5%
Other Income 1362518253410736110732778185157542474388 +109.3% -18.1%
Interest 888590911041061159697155138114116116 -25.4% +0.0%
Depreciation 122120121125128131131134132128130136144151 +18.0% +4.6%
Profit Before Tax 3856151,0129685741,6852,2341,0394973,6754751,4443522,111 -42.6% +499.0%
Net Profit 2564917818054501,4051,7017904712,8143851,1572961,722 -38.8% +480.8%
EPS 2.534.857.717.954.4513.8916.907.854.6827.963.8211.492.9517.11 -38.8% +480.0%
OPM % 22.0% 29.9% 38.6% 30.1% 29.5% 47.1% 57.0% 35.9% 25.8% 64.8% 22.6% 40.1% 8.7% 53.2% -17.9% +511.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹15,117 Cr ₹11,484 Cr ₹11,484 Cr -24.0%
Operating Profit ₹7,736 Cr ₹3,925 Cr ₹3,925 Cr -49.3%
OPM % 51.18% 34.18% 34.18% -33.2%
NPM % 38.20% 31.00% 31.00% -18.8%
Other Income ₹696 Cr ₹1,561 Cr ₹1,561 Cr +124.1%
Depreciation ₹524 Cr ₹561 Cr ₹561 Cr +7.1%
Interest ₹464 Cr ₹484 Cr ₹484 Cr +4.2%
EBIT ₹7,212 Cr ₹3,364 Cr ₹3,364 Cr -53.4%
PBT ₹7,444 Cr ₹4,382 Cr ₹4,382 Cr -41.1%
Tax ₹1,420 Cr ₹146 Cr ₹146 Cr -89.7%
Net Profit ₹5,775 Cr ₹3,560 Cr ₹3,560 Cr -38.4%
EPS ₹57.39 ₹35.37 ₹35.37 -38.4%
Material Cost ₹2,287 Cr ₹1,788 Cr ₹1,788 Cr -21.9%
Employee Cost ₹1,326 Cr ₹984 Cr ₹984 Cr -25.8%
Extraordinary Items — ₹60 Cr ₹60 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 101101101101 +0.0%
Reserves 13,53815,61621,09023,571 +11.8%
Borrowings 4,8256,1788,3427,442 -10.8%
Other Liabilities 2,0992,1902,7852,766 -0.7%
Total Liabilities 20,56424,08532,31733,880 +4.8%
Fixed Assets 4,1844,3694,2025,084 +21.0%
CWIP 7396341,188621 -47.7%
Investments 4,8797,28311,49211,478 -0.1%
Other Assets 10,76111,79815,43516,696 +8.2%
Total Assets 20,56424,08532,31733,880 +4.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,0782,0003,1142,234 -28.3%
Cash from Investing Activity -1,959-1,832-4,504570 +112.7%
Cash from Financing Activity 827-3011,384-2,580 -286.4%
Net Cash Flow -54-132-5224 +4580.0%
Free Cash Flow 4201,4342,2571,351 -40.1%
CFO/OP 60%71%58%84% +44.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 147160197270 +37.1%
Inventory Days 205195236222 -5.9%
Days Payable 120129149150 +0.7%
Cash Conversion Cycle 232227284342 +20.4%
Working Capital Days 16416774315 +325.7%
ROCE % 14%23%31%17% -45.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 75.00%75.00%75.00%75.00%75.01% +0.0%
FIIs 7.13%7.34%7.06%6.95%7.05% +1.4%
DIIs 11.09%10.86%11.08%11.20%11.28% +0.7%
Government 0.04%0.00%0.00%0.00%— —
Public 6.74%6.81%6.86%6.86%6.66% -2.9%
No. of Shareholders 3,86,1273,96,1054,03,2664,18,3143,82,067 -8.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Zydus Lifesciences Limited's revenue in Q4 FY26?
Zydus Lifesciences Limited reported revenue of ₹3,741 crore for the quarter ended March 2026 (Q4 FY26), down 35.7% from ₹5,820 crore in the same quarter last year, and up 63.8% sequentially over the December 2025 quarter.
What was Zydus Lifesciences Limited's net profit in Q4 FY26?
Net profit fell 38.8% year-on-year to ₹1,722 crore, from ₹2,814 crore. Earnings per share (EPS) came in at ₹17.11.
What is ZYDUSLIFE's market capitalisation and P/E ratio?
At the current price of ₹1,123.00, ZYDUSLIFE has a market capitalisation of ₹112,020 crore and a trailing P/E of about 31.5.
Who owns Zydus Lifesciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 75.01%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 11.28%, public shareholders 6.66% of Zydus Lifesciences Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI